Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Life sciences business development company Bio-Link Australia has entered into an agreement to commercialize Phylogica's anti-inflammatory Phylomer peptides for pharmaceutical use.
Subscribe to our email newsletter
The family of anti-inflammatory Phylomer peptides including PYC35, PYC36, PYC38 and PYC98, which targets the AP-1 pathway, have demonstrated efficacy in multiple preclinical models for stroke, traumatic brain injury and acute respiratory distress syndrome (ARDS).
Under the agreement, Bio-Link will work with Phylogica to monetize the assets through out-licensing or disposal of the Phylomer peptides to a pharmaceutical or biotechnology company.
The commercialization will be supported by a grant of $20,000 from the Western Australian government under the Innovation Vouchers Program (IVP), a part of the government’s Translating Research Scheme.
Phylogica chief executive officer Paul Watt said, "We look forward to working with them to accelerate partnerships around these Phylomers, while Phylogica’s management team maintains its focus on building the Company’s drug discovery alliance activities."
Phylogica has also received a European patent (05773610.0), which covers formulations of Phylomer peptides for the treatment of ischemia.